IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: We found there is a negative correlation of SCF with IL-6 in CML patients (Figure 6B), indicating that higher IL-6 could inhibit MSCs to secrete SCF and impair normal HSPC proliferation, thus promote CML progression.